Welcome! Login | Register
 

College Admissions: Why Starting in 9th Grade Matters—Every fall, I see families of seniors in…

Leonard Moorehead, The Urban Gardener: Harvesting Green Beans + Sunflowers—Gardening made simple...

Buddy Guy Brings the Blues to Indian Ranch—The reigning champion of the Chicago Blues was…

College Admissions: 6 Steps To A Killer College Application—Put your best food forward...

Where to WOO? - Week of August 20, 2015—Where to WOO? - Week of August 20,…

10 Great Pets in Need of Loving Homes - August 18, 2015—10 Great Pets in Need of Loving Homes…

With Heroin Deaths Rising Sharply, White House Announces New Initiative—With Heroin Deaths Rising Sharply, White House Announces…

College Admissions: 4 New England College Roadtrips—Take advantage of the best time to see…

Where will you WOO? Week of August 13—Where will you WOO? Week of August 13

3rd Annual UnCommon Job Fair to be Held September 4—3rd Annual UnCommon Job Fair

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.